Digital PCR (dPCR) enables nucleic acid quantification with superior accuracy, precision and relative sensitivity. This technology excels in:
As absolute concentrations are determined, data can be easily interpreted and compared across different samples and experiments, especially in a clinical setting.
Related topics: copy number analysis, mutation detection, fusion gene detection, custom primer design, sample preparation, clinical trials, biomarker test development, liquid biopsies, data analysis
“My key reasons for choosing Biogazelle as a service provider is
Biogazelle's expertise with qPCR and ddPCR, and the possibility to
perform ddPCR feasibility studies.”
Principal Research Scientist at top 10 pharma company (Belgian division)
Over the years, Biogazelle has performed various dPCR projects for its customers, both in research and clinical trial settings, including:
Biogazelle is at the forefront of dPCR-based research, as it was one of the first European laboratories that had access to the technology in 2012. Biogazelle’s co-founders Dr Jan Hellemans and Prof. Jo Vandesompele are co-authors on the digital MIQE guidelines. Biogazelle is also serving as a reference laboratory for Bio-Rad’s QX200 Digital Droplet PCR system in Europe and uses its experience to provide digital PCR services, including dPCR assay design using our proprietary primerXL design engine. Digital PCR services are performed in an ISO17025 accredited environment and following the good clinical laboratory practice (GCLP) guidelines, allowing us to analyze samples in clinical trials.
Technologiepark 82
B-9052 Zwijnaarde
Belgium
email: info@biogazelle.com
phone: +32 9 245 96 43
fax: +32 9 251 56 56